AI Think Tank: Biotech Bay

Jennifer Kilroy is SVP, Head of Strategy & Transformation at Syner-G, where she partners with pharmaceutical, biotechnology, and medical device organizations to accelerate business performance through strategic transformation, AI adoption, digital innovation, and M&A integration. With more than two decades of experience leading enterprise transformation initiatives, she is recognized for her ability to bridge strategy, technology, and people, advising executive leadership teams on responsibly adopting AI while keeping patient outcomes, workforce readiness, and regulatory expectations front and center.

Jennifer is a passionate advocate for human-centric AI and frequently speaks on its future across research, development, manufacturing, and business operations in life sciences. Through her team’s “3D Intelligence” model, organizations have improved the return on their AI investments by driving workforce adoption, efficiency, and effectiveness. At Syner-G, she leads a multidisciplinary team of consultants in strategy, program management, change management, and organizational development, helping clients navigate digital modernization, portfolio growth, and post-merger integration. Jennifer holds a PhD in Business Management, an Executive MBA, and an MBS in Human Resource Management, and is certified in executive coaching and Lean Six Sigma.

Nathan Jack is a strategic partner to senior leaders driving innovation at the intersection of people, process, and performance. With deep expertise in Lean Six Sigma, program management, and operational transformation, Nathan helps life sciences organizations implement scalable solutions that empower teams, reduce risk, and accelerate growth.

Nathan’s approach is grounded in ‘people-first’ leadership. He works shoulder-toshoulder with executives and frontline teams to re-imagine and co-create processes while building resilient, high-performing teams. From strategy deployment to execution, he challenges the status quo, builds alignment, and fosters ownership, so your teams can innovate and unlock hidden value for your business.

Nathan is known for his ability to translate complexity into clarity — calmly guiding organizations through transformations to move forward and deliver results. In previous roles at Thermo Fisher Scientific and other industry leading companies, Nathan has led enterprise-wide initiatives to deliver multimillion-dollar savings, enhance team safety, improve process quality, and enable operational agility.

Hailey Clark is CEO of ASMBL, a 15-year professional services organization that has delivered technology for Fortune 10 companies, growth-stage businesses and everything in between. A strategist, entrepreneur and systems thinker, she has spent more than 15 years building businesses and leading teams across North America and Europe. Her work sits at the intersection of technology, human potential and complex systems — shaped early in her career in sport and entertainment, where she worked alongside organizations including Hockey Canada, USA Hockey, the NHL and Bauer to use technology, data and connected experiences to strengthen participation, performance and community.

Today, Hailey is leading ASMBL’s evolution into an AI-native professional services company and the development of its Coherence System — connecting agentic technology with highly skilled delivery experts, strategists, builders and visionaries to help organizations deploy and scale technology effectively. Her focus is on health, biotech and wellness — complex human systems where technology can improve care, strengthen connection and ultimately serve humanity. She sees our role not simply as adopters of AI, but as stewards of what we choose to build: “If we use AI to optimize the world exactly as it exists today, we may simply recreate our past at extraordinary speed. The opportunity is to decide what future we actually want, and then put AI in service of building it.

Rachel Fournier is Senior Director, AI & Digital Innovation at Vera Therapeutics, where she helps shape the company’s approach to AI and emerging digital technologies.

Drawing on experience across biotechnology, healthcare, and technology companies, she brings a cross-industry perspective to how AI can be translated from rapidly evolving capabilities into practical business value. Her work focuses on identifying high-value AI opportunities, enabling responsible adoption, and helping teams apply new technologies in ways that improve decision-making, productivity, and innovation.

Rachel is particularly interested in what biotech can learn from the technology sector while adapting those approaches to the unique scientific, operational, and regulatory realities of biopharma. She approaches AI transformation as both a technology and organizational challenge, connecting business needs, people, and scalable solutions to help organizations move from experimentation to meaningful adoption.